Skip to main content

Iterum Therapeutics plc

ITRMDelisted Jun 23, 2026
Industry
Pharmaceutical Preparations
SEC CIK
0001659323

Iterum Therapeutics plc was delisted on Jun 23, 2026; its insiders filed their last Form 4 on Nov 20, 2025; 18 institutions reported holding it in 13F filings for Q1 2026, worth $41.3K in total; no superinvestor held it.

Key figures

Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
18
Q1 2026, −2 vs. previous quarter
13F value
$41.3K
Reported value at the end of Q1 2026
Superinvestors holding
0
At the end of Q1 2026

Superinvestors holding ITRM, Q1 2026

Go to the superinvestors tab

No superinvestor reported holding ITRM at the end of Q1 2026.

Latest insider trades

Open-market purchases and sales by Iterum Therapeutics plc insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 20, 2025 (view filing)7:00 AM ETNov 182 daysDunne Michael W.DirectorPPurchase+6.00K$0.3652+$2.19K+2.6%241.0K after
Aug 12, 2025 (view filing)Aug 84 daysDunne Michael W.DirectorPPurchase+15.0K$0.72+$10.8K+6.8%235.0K after
Dec 27, 2023 (view filing)Dec 225 daysDunne Michael W.DirectorPPurchase+25.0K$1.40+$35.0K+28.2%113.8K after
Dec 19, 2023 (view filing)Dec 181 dayDunne Michael W.DirectorPPurchase+10.0K$1.84+$18.4K+12.7%88.8K after
Nov 27, 2023 (view filing)Nov 225 daysDunne Michael W.DirectorPPurchase+20.0K$2.03+$40.6K+34.0%78.8K after
Nov 20, 2023 (view filing)Nov 20Same dayFishman Corey N.Chief Executive OfficerPPurchase+10.0K$1.59+$15.9K+22.5%54.4K after
Dec 5, 2022 (view filing)Dec 23 daysPuttagunta SailajaChief Medical OfficerSSale−3.37K$1.32−$4.44K−40.4%4.97K after
Sep 20, 2022 (view filing)Sep 16-204 daysAhrens Brenton KarlDirectorSSale−37.2K$1.82−$67.9K−100.0%0 after3 lots
Sep 15, 2022 (view filing)Sep 13-152 daysAhrens Brenton KarlDirectorSSale−45.0K$2.09−$93.9K−54.7%37.2K after3 lots
Sep 12, 2022 (view filing)Sep 8-124 daysAhrens Brenton KarlDirectorSSale−33.3K$2.31−$76.9K−28.8%82.2K after3 lots

Top 10 13F holders, Q1 2026

The largest institutional positions in Iterum Therapeutics plc at the end of Q1 2026; share changes are against Q4 2025.

See all 18 holders
Institutions holding ITRM in Q1 2026
InstitutionSharesValue% of portfolioChange in sharesAction
HRT Financial LP890,083$26.0K0.00%+890,083New
Captrust Financial Advisors138,600$4.16K0.00%00.0%Unchanged
Gen-Wealth Partners Inc82,617$2.48K0.00%−2,013−2.4%Reduced
Jump Financial, LLC72,156$2.17K0.00%+72,156New
Krilogy Financial LLC69,761$1.74K0.00%+29,761+74.4%Added
XTX Topco Ltd49,380$1.48K0.00%+49,380New
MAI Capital Management35,000$1.05K0.00%+35,000New
SG Americas Securities, LLC33,464$1.00K0.00%+20,682+161.8%Added
Flagship Harbor Advisors, LLC20,000$6000.00%+20,000New
Morgan Stanley15,713$4710.00%+10,000+175.0%Added